First Author​

Abstract title​

Presentation type and #​

Prurigo nodularis

S. Ständer

Nemolizumab monotherapy improves itch and skin lesions in patients with moderate-to-severe prurigo nodularis: Results from a global phase 3 trial (OLYMPIA 1)

Late-breaking presentation D1T01.1D

Wednesday, October 11

3:00 – 3:15 PM CEST

Hall B

A. Reich

Nemolizumab modulates prurigo nodularis-associated skin pain and markedly improves patient reported outcomes in patients with moderate-to-severe prurigo nodularis in a phase 3 study (OLYMPIA 2)

e-poster​ P0486

S. Kwatra

The burden of disease for prurigo nodularis in a commercially and Medicare-insured U.S. population: A retrospective cohort study

e-poster​ P2290

M. Z. Joel

Risk of itch-induced sleep deprivation and subsequent mental health comorbidities in patients with prurigo nodularis: A population-level analysis using the Health Improvement Network

e-poster​ P2299

U. Choi

Prurigo nodularis patients with and without comorbid atopic dermatitis exhibit different clinical characteristics and treatment response

e-poster​ P1958

Atopic dermatitis​

J. Silverberg

Nemolizumab improves skin lesions, itch and sleep disturbance in patients with moderate-to-severe atopic dermatitis: Results from two identical phase 3 multinational studies (ARCADIA 1 and ARCADIA 2)

Late-breaking presentation D1T01.1C

Wednesday, October 11

2:45 – 3:00 PM CEST

Hall B

S. Anjuwon

Management of sensitive skin with Atopic Dermatitis: an extensive clinical program demonstrating the efficacy and safety of a flare-up relieve cream

e-poster​ P0519

Rosacea

B. Homey

Dysbiosis in rosacea and its modulation by topical ivermectin

Late-breaking presentation D2T01.3D

Thursday, October 12

3:00 – 3:15 PM CEST

Hall B

Acne

A. Andrew

Efficacy and safety of trifarotene cream 50µg/g for the treatment of acne-induced post-inflammatory hyperpigmentation in subjects with Fitzpatrick Skin Types I-VI: Results from a phase IV trial (LEAP)

e-poster​ P0131

S. Schleicher

Evaluation of risk of formation of atrophic acne scars during acne treatment with trifarotene 50μg/g cream versus vehicle cream: Results from a phase 4, randomised, double-blind, split-face, vehicle-controlled clinical study (START)

e-poster​ P0127

N. Piccardi

A tailored skincare routine provides benefits to patients with moderate acne vulgaris and post-inflammatory hyperpigmentation in combination with topical trifarotene

e-poster​ P0027

Sensitive skin and healthy aging

I. Berlin

Diversity and inclusion in dermatology: a worldwide profiling of sensitive skin

e-poster​ P1524

G. Pellacani

An innovative tailored approach to manage healthy aging in sensitive skin

e-poster​ P0923

M. Grivet

Sensitive skin syndrome: a meta-analysis of clinical trials evaluating the impact of dermocosmetics on itch

e-poster​ P2302

N. Joly-Tonetti

Niacinamide: a versatile anti-aging molecule against environmental stressors – new learnings from the mitochondrial physiology

 e-poster​ P0922